AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10962855 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U calcitonin thrice a week for 3 months
Number of subjects: 41
Study 10962855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8819498 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine maintenance (8 mg/day with p.o. placebo)
Number of subjects: 12
Study 8819498 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance (80 mg/day)
Number of subjects: 12
Study 8819498 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine maintenance
Number of subjects: 12
Study 8819498 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance
Number of subjects: 12
Study 1394960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonifying Manipulation (TM)
Number of subjects: 0
Study 1394960 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing Manipulation (RM)
Number of subjects: 0
Study 1394960 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 3864038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmune hepatitis B immunoglobulin (HBIg) administered at birth and six weeks
Number of subjects: 100
Study 3864038 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 100
Study 3864038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers who were HBsAg positive but hepatitis Be antigen negative
Number of subjects: 100
Study 29982413 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Activity Monitoring (RAM)
Number of subjects: 132
Study 29037773 — intervention group
Group type: EXPERIMENTAL
Intervention: S+NAC500 (simethicone 200 mg + N-acetylcysteine 500 mg)
Number of subjects: 230
Study 29037773 — intervention group
Group type: EXPERIMENTAL
Intervention: S+NAC1000 (simethicone 200 mg + N-acetylcysteine 1000 mg)
Number of subjects: 230
Study 29037773 — intervention group
Group type: EXPERIMENTAL
Intervention: S (simethicone 200 mg)
Number of subjects: 230
Study 29037773 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 230
Study 29037773 — intervention group
Group type: COMPARATOR
Intervention: Water (100 mL)
Number of subjects: 230
Study 26952680 — intervention group
Group type: EXPERIMENTAL
Intervention: Finding Balance Intervention (FBI)
Number of subjects: 19
Study 26952680 — intervention group
Group type: COMPARATOR
Intervention: Control group (received FBI at a second visit)
Number of subjects: 19
Study 24013857 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-breathing phase contrast (PC) imaging
Number of subjects: 6
Study 24013857 — intervention group
Group type: COMPARATOR
Intervention: Breath-hold phase contrast (PC) imaging
Number of subjects: 6
Study 24013857 — intervention group
Group type: COMPARATOR
Intervention: Tissue Doppler imaging (TDI)
Number of subjects: 6
Study 22642853 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention group
Number of subjects: 140
Study 22642853 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 140
Study 20205485 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 18568571 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 132
Study 18568571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 16024862 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg intravenously before and after surgery, continued orally for 4 days at 20 mg/kg/8 hours)
Number of subjects: 62
Study 16024862 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 62
Study 16024862 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 62
Study 12180109 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-day catheter dressing change frequency
Number of subjects: 112
Study 12180109 — intervention group
Group type: COMPARATOR
Intervention: 4-day catheter dressing change frequency
Number of subjects: 112
Study 10335412 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic remedies
Number of subjects: 100
Study 10335412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7492197 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (100 micrograms/puff, two puffs twice daily for eight weeks)
Number of subjects: 50
Study 7492197 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two puffs twice daily for eight weeks)
Number of subjects: 50
Study 8185085 — intervention group
Group type: EXPERIMENTAL
Intervention: AES followed by saline (AS)
Number of subjects: 40
Study 8185085 — intervention group
Group type: EXPERIMENTAL
Intervention: AES followed by naloxone (AN)
Number of subjects: 40
Study 8185085 — intervention group
Group type: COMPARATOR
Intervention: Placebo AES followed by saline (PS)
Number of subjects: 40
Study 8185085 — intervention group
Group type: COMPARATOR
Intervention: Placebo AES followed by naloxone (PN)
Number of subjects: 40
Study 3940829 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 24
Study 3940829 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 24
Study 3940829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 24
Study 3940829 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 24
Study 30160313 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with BMMNC graft
Number of subjects: 42
Study 30160313 — intervention group
Group type: COMPARATOR
Intervention: CABG only
Number of subjects: 42
Study 26363250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar fusion
Number of subjects: 294
Study 26363250 — intervention group
Group type: COMPARATOR
Intervention: Non-specific physiotherapy (control)
Number of subjects: 294
Study 26363250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar fusion and Non-specific physiotherapy
Number of subjects: 294
Study 24231197 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen tube (DLT)
Number of subjects: 52
Study 24231197 — intervention group
Group type: COMPARATOR
Intervention: Bronchial blocker (BB)
Number of subjects: 52
Study 24231197 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial blocker with disconnection technique (BB with disconnection)
Number of subjects: 52
Study 21975468 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise programme (increased to 3000 steps more than before)
Number of subjects: 40
Study 21975468 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 20683173 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat plus L-carnitine (orlistat 120 mg three times a day plus L-carnitine 2 g one time a day)
Number of subjects: 258
Study 20683173 — intervention group
Group type: COMPARATOR
Intervention: Orlistat (orlistat 120 mg three times a day)
Number of subjects: 258
Study 18762633 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent articaine with 1:100,000 epinephrine
Number of subjects: 73
Study 18762633 — intervention group
Group type: COMPARATOR
Intervention: 2 percent lidocaine with 1:100,000 epinephrine
Number of subjects: 73
Study 16122669 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 72
Study 16122669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 16122669 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 12594639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonchlamydial antigen immunization (yellow fever, polio, diphtheria, and tetanus)
Number of subjects: 48
Study 12594639 — intervention group
Group type: COMPARATOR
Intervention: Saline injections (placebo)
Number of subjects: 48
Study 9803652 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laparoscopy
Number of subjects: 882
Study 7986714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy with blood progenitor transplantation (priming regimen: cyclophosphamide 3 g/m2, etoposide 900 mg/m2 with GM-CSF; high-dose chemotherapy: thiotepa 750 mg/m2, busulfan 10 mg/kg, cyclophosphamide 120 mg/kg)
Number of subjects: 17
Study 7986714 — intervention group
Group type: COMPARATOR
Intervention: Control patients who did not receive intensive treatment
Number of subjects: 17
Study 3236383 — intervention group
Group type: EXPERIMENTAL
Intervention: Written behavioral prescriptions
Number of subjects: 30
Study 3236383 — intervention group
Group type: COMPARATOR
Intervention: Verbal behavioral prescriptions
Number of subjects: 30
Study 5090761 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg twice daily)
Number of subjects: 3
Study 5090761 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-K (32 mEq daily)
Number of subjects: 3
Study 5090761 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene (50 mg twice daily)
Number of subjects: 3
Study 31365801 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib-rituximab
Number of subjects: 529
Study 31365801 — intervention group
Group type: COMPARATOR
Intervention: chemoimmunotherapy
Number of subjects: 529
Study 28918642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral healthcare program administered for 8 weeks
Number of subjects: 46
Study 28918642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 26687696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg SC every 2 weeks (Q2W)
Number of subjects: 361
Study 26687696 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/d
Number of subjects: 361
Study 26687696 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/d (rechallenge)
Number of subjects: 361
Study 24490169 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire Flow Restoration
Number of subjects: 51
Study 24490169 — intervention group
Group type: COMPARATOR
Intervention: Merci/Penumbra systems
Number of subjects: 51
Study 21636808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1 g of vitamin C
Number of subjects: 56
Study 21636808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18088263 — intervention group
Group type: EXPERIMENTAL
Intervention: Community nurse visits before discharge, within seven days of discharge, weekly for four weeks, then monthly.
Number of subjects: 105
Study 18088263 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard follow-up in specialist medical clinics)
Number of subjects: 105
Study 16423737 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to psychological stressor
Number of subjects: 0
Study 12603639 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 2113
Study 12603639 — intervention group
Group type: COMPARATOR
Intervention: sumatriptan 100 mg
Number of subjects: 2113
Study 12603639 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2113
Study 10860187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injection therapy (MIT)
Number of subjects: 110
Study 10860187 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin injection therapy (CIT)
Number of subjects: 110
Study 9263111 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicus double-needle plateletapheresis
Number of subjects: 30
Study 9263111 — intervention group
Group type: COMPARATOR
Intervention: Amicus single-needle procedures
Number of subjects: 30
Study 9263111 — intervention group
Group type: COMPARATOR
Intervention: Amicus
Number of subjects: 30
Study 7684080 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven pediculicidal agents with their supplied nit removal combs
Number of subjects: 223
Study 7684080 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 223
Study 2949059 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 38393 (selective D‐1 dopamine receptor agonist)
Number of subjects: 7
Study 2949059 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 38393 combined with intravenous levodopa
Number of subjects: 7
Study 2949059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30261898 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin
Number of subjects: 1741
Study 30261898 — intervention group
Group type: COMPARATOR
Intervention: Crystalloids
Number of subjects: 1741
Study 27687435 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope
Number of subjects: 60
Study 27687435 — intervention group
Group type: COMPARATOR
Intervention: Lightwand
Number of subjects: 60
Study 25614126 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanols (2 g)
Number of subjects: 36
Study 25614126 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (2 g)
Number of subjects: 36
Study 25614126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol
Number of subjects: 36
Study 25614126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitosterol
Number of subjects: 36
Study 25614126 — intervention group
Group type: COMPARATOR
Intervention: Control (margarine without plant stanols/sterols)
Number of subjects: 36
Study 23549137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic containing urea, lactate, polidocanol, and Glycyrrhiza inflata root extract applied three times a week for 4 weeks.
Number of subjects: 30
Study 23549137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic containing urea and lactate.
Number of subjects: 30
Study 23549137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic treatment.
Number of subjects: 30
Study 20956842 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Circuit Training (FCT)
Number of subjects: 51
Study 20956842 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 51
Study 19125830 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity mannequin (SimMan)
Number of subjects: 12
Study 19125830 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity mannequin (Laerdal Heart Start 2000)
Number of subjects: 12
Study 19125830 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective outcomes
Number of subjects: 12
Study 17277653 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (LPLC)
Number of subjects: 40
Study 17277653 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum
Number of subjects: 40
Study 12689847 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 43
Study 12689847 — intervention group
Group type: COMPARATOR
Intervention: Conventional-weaning approach
Number of subjects: 43
Study 10389553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg
Number of subjects: 861
Study 10389553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 180 mg
Number of subjects: 861
Study 10389553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study 8891185 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mG intermittent, circularly polarized magnetic fields
Number of subjects: 73
Study 8891185 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 73
Study 8891185 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mG field condition
Number of subjects: 73
Study 8891185 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (night 1)
Number of subjects: 73
Study 2004528 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic combination of EE:CHOL (50 mg of mixture providing 0.050 mg of ethinylestradiol)
Number of subjects: 6
Study 2004528 — intervention group
Group type: COMPARATOR
Intervention: 50 micrograms tablet of ethinylestradiol (Dianor, Syntex)
Number of subjects: 6
Study 2004528 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic combination of EE:CHOL
Number of subjects: 6
Study 7047686 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine therapy (2 mg/kg/day)
Number of subjects: 115
Study 7047686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with cytostatics)
Number of subjects: 115
Study 31543215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) as a periprocedural bridging anticoagulant
Number of subjects: 9278
Study 29936918 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1.25 mg vitamin D3 monthly for 24 months)
Number of subjects: 200
Study 29936918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 29936918 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently vitamin D sufficient (25(OH)D>50 nmol/l at both months 3 and 24)
Number of subjects: 200
Study 29936918 — intervention group
Group type: COMPARATOR
Intervention: Not consistently vitamin D sufficient (25(OH)D≤50 nmol/l at either month 3 or 24)
Number of subjects: 200
Study 27384676 — intervention group
Group type: EXPERIMENTAL
Intervention: DDGP regimen (cisplatin, dexamethasone, gemcitabine, pegaspargase); 6 cycles of chemotherapy
Number of subjects: 25
Study 25102730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin administration combined with standard therapy
Number of subjects: 0
Study 25102730 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 0
Study 21319349 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole prophylaxis
Number of subjects: 55
Study 21319349 — intervention group
Group type: COMPARATOR
Intervention: Empirical treatment
Number of subjects: 55
Study 19390459 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 190
Study 19390459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 19390459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Olmesartan + Pravastatin)
Number of subjects: 190
Study 19390459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 190
Study 16427787 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 0
Study 16427787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12632691 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education program
Number of subjects: 428
Study 11789242 — intervention group
Group type: EXPERIMENTAL
Intervention: Changmaishu (CMS)
Number of subjects: 80
Study 11789242 — intervention group
Group type: COMPARATOR
Intervention: Salvia injection and Di'ao Xinxuekang (Control)
Number of subjects: 80
Study 9375537 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 10% MVC for 65 min (test B)
Number of subjects: 12
Study 9375537 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 10% MVC following maximum contraction for 4 min (test A)
Number of subjects: 12
Study 1549521 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2 degrees C blanket
Number of subjects: 89
Study 1549521 — intervention group
Group type: EXPERIMENTAL
Intervention: 23.9 degrees C blanket
Number of subjects: 89
Study 1549521 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmer blanket temperatures
Number of subjects: 89
Study 1549521 — intervention group
Group type: COMPARATOR
Intervention: All groups (7.2, 12.8, 18.3, 23.9 degrees C)
Number of subjects: 89
Study 4028810 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lormetazepam
Number of subjects: 6
Study 4028810 — intervention group
Group type: COMPARATOR
Intervention: 2 mg flunitrazepam
Number of subjects: 6
Study 30995350 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Re‐timer®
Number of subjects: 15
Study 30995350 — intervention group
Group type: COMPARATOR
Intervention: Placebo Re‐timer® (dimmer with neutral density filters)
Number of subjects: 15
Study 29025406 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/die
Number of subjects: 75
Study 29025406 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg/die
Number of subjects: 75
Study 26736984 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin with itraconazole
Number of subjects: 0
Study 26736984 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 0
Study 24029022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided combined sciatic-femoral nerve block (USFB) with a 25 ml mixture (10 ml of 2.0% lidocaine, 10 ml of 0.5% levobupivacaine, and 5 ml of saline)
Number of subjects: 40
Study 24029022 — intervention group
Group type: COMPARATOR
Intervention: Unilateral spinal anaesthesia (USA) with 2 ml (10 mg) of 0.5% levobupivacaine
Number of subjects: 40
Study 22052141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 39
Study 22052141 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 39
Study 19349078 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (mean dose 125 mg daily)
Number of subjects: 171
Study 19349078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 16700824 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (27.9±14.8 mg/kg/24 hr)
Number of subjects: 30
Study 16700824 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 30
Study 15063241 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:yttrium‐aluminum‐garnet TMR (n = 100)
Number of subjects: 212
Study 15063241 — intervention group
Group type: COMPARATOR
Intervention: Continued medical management (n = 112)
Number of subjects: 212
Study 11056853 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial hemoglobin level (Hb) < median (13.5 g/dl)
Number of subjects: 125
Study 11056853 — intervention group
Group type: EXPERIMENTAL
Intervention: Total tumor volume (TTV) > median (98 ml)
Number of subjects: 125
Study 11056853 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe anemia (Hb < 10 g/dl)
Number of subjects: 125
Study 11056853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 125
Study 11056853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor oxygenation
Number of subjects: 125
Study 11056853 — intervention group
Group type: EXPERIMENTAL
Intervention: Other parameters examined
Number of subjects: 125
Study 9067045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 5 micrograms.kg‐1
Number of subjects: 20
Study 9067045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20